FDA 批准符合条件的个人长期使用基于 semaglutide 的 Wegovy 减肥药。 FDA approves long-term use of semaglutide-based Wegovy weight loss drug for eligible individuals.
含有西马格卢提德的减肥药Wegovy已获得FDA的批准,可长期使用给BMI为30或更高或27或更高的患者. Wegovy, a weight loss drug containing semaglutide, has been approved by the FDA for long-term use in individuals with a BMI of 30 or higher, or 27 or greater with other conditions. 这种药物模仿GLP-1激素,导致食欲抑制,减少卡路里摄入量,增加腹感,导致显著的体重减轻. The medication mimics the GLP-1 hormone, leading to appetite suppression, reduced calorie intake, and increased satiety, resulting in significant weight loss. 潜在副作用包括恶心、腹泻、便秘和呕吐,其副作用较罕见,包括胰腺炎、胆囊病和肾病。 Potential side effects include nausea, diarrhea, constipation, and vomiting, with rarer side effects including pancreatitis, gallbladder disease, and kidney problems. Wegovy与其用于治疗2型糖尿病的姐妹药物Ozempic不同。 Wegovy differs from its sister medication, Ozempic, which is used for treating type 2 diabetes. 这两种药物都没有通过澳大利亚药品福利计划得到补贴,导致使用者的价格高。 Both drugs are not subsidized through Australia's Pharmaceutical Benefits Scheme, leading to a high price tag for users.